11 documents found, page 1 of 2
Clinical validation of a urine test (uromonitor-V2(®)) for the surveillance of ...
Sieverink, CA; Batista, R; Prazeres, H; Vinagre, J; Sampaio, C; Leão, RR; Máximo, V; Alfred Witjes, J; Soares, PThe costly and burdensome nature of the current follow-up methods in non-muscle-invasive bladder cancer (NMIBC) drives the development of new methods that may alternate with regular cystoscopy and urine cytology. The Uromonitor-V2® is a new urine-based assay in the detection of hotspot mutations in three genes (TERT, FGFR3, and KRAS) for evaluation of disease recurrence. The aim of this study was to investigate...
Biomarkers for bladder cancer diagnosis and surveillance: A comprehensive review
Batista, R; Vinagre, N; Meireles, S; Vinagre, J; Prazeres, H; Leão, R; Máximo, V; Soares, PBladder cancer (BC) ranks as the sixth most prevalent cancer in the world, with a steady rise in its incidence and prevalence, and is accompanied by a high morbidity and mortality. BC is a complex disease with several molecular and pathological pathways, thus reflecting different behaviors depending on the clinical staging of the tumor and molecular type. Diagnosis and monitoring of BC is mainly performed by in...
TERT promoter mutation as a potential predictive biomarker in BCG-treated bladd...
Batista, R; Lima, L; Vinagre, J; Pinto, V; Lyra, J; Máximo, V; Santos, L; Soares, PTelomerase reverse transcriptase gene promoter (TERTp) mutations are recognized as one of the most frequent genetic events in bladder cancer (BC). No studies have focused on the relevance of TERTp mutations in the specific group of tumors treated with Bacillus Calmette–Guérin (BCG) intravesical therapy. Methods — 125 non muscle invasive BC treated with BCG therapy (BCG-NMIBC) were screened for TERTp mutations, ...
Prognostic significance of RAS mutations and P53 expression in cutaneous squamo...
Campos, MA; Macedo, S; Fernandes, MS; Pestana, A; Pardal, J; Batista, R; Vinagre, J; Sanches, A; Baptista, A; Lopes, JM; Soares, PTP53 is considered the most commonly-altered gene in cutaneous squamous cell carcinoma (cSCC). Conversely, RAS mutations have been reported in a low percentage of cSCC. The objective of our study was to evaluate the frequency of p53 expression and RAS mutations in cSCC and correlate them with clinicopathological features and patient outcome. We performed immunohistochemistry for p53 and genetic profiling for RA...
Erratum to “Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in...
Santos, AP; Vinagre, J; Soares, P; Claro, I; Sanches, AC; Gomes, L; Fernandes, I; Catarino, AL; Preto, J; Pereira, BD; Marques, AP; Rodrigues, FIn the article titled "Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism"[1], the affiliation for I. Claro was labeled incorrectly. The correct affiliation of the author I. Claro is Instituto Portugûes de Oncologia de Lisboa, Francisco Gentil (IPOLFG), 1099-023 Lisboa, Portugal.
Molecular aspects of thyroid calcification
Ferreira, LB; Gimba, E; Vinagre, J; Sobrinho-Simões, M; Soares, PIn thyroid cancer, calcification is mainly present in classical papillary thyroid carcinoma (PTC) and in medullary thyroid carcinoma (MTC), despite being described in benign lesions and in other subtypes of thyroid carcinomas. Thyroid calcifications are classified according to their diameter and location. At ultrasonography, microcalcifications appear as hyperechoic spots = 1 mm in diameter and can be named as ...
Gastroenteropancreatic neuroendocrine neoplasia characterization in portugal: R...
Santos, AP; Vinagre, J; Soares, P; Claro, I; Sanches, AC; Gomes, L; Fernandes, I; Catarino, AL; Preto, J; Pereira, BD; Marques, AP; Rodrigues, FBackground. The incidence of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) has been increasing in the last five decades, but there is no large-scale data regarding these tumours in Portugal. We conducted a cross-sectional, multicentric study in main Portuguese centers to evaluate the clinical, pathological, and therapeutic profile of GEP-NENs. Methods. From November, 2012, to July, 2014, data from ...
Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence ...
Batista, R; Vinagre, J; Prazeres, H; Sampaio, C; Peralta, P; Conceição, P; Sismeiro, A; Leão, R; Gomes, A; Furriel, F; Oliveira, C; Torres, JNBladder cancer (BC), the most frequent malignancy of the urinary system, is ranked the sixth most prevalent cancer worldwide. Of all newly diagnosed patients with BC, 70–75% will present disease confined to the mucosa or submucosa, the non-muscle-invasive BC (NMIBC) subtype. Of those, approximately 70% will recur after transurethral resection (TUR). Due to high rate of recurrence, patients are submitted to an i...
Telomere maintenance mechanisms in cancer
Gaspar, TB; Sá, A; Lopes, JM; Sobrinho-Simões, M; Soares, P; Vinagre, JTumour cells can adopt telomere maintenance mechanisms (TMMs) to avoid telomere shortening, an inevitable process due to successive cell divisions. In most tumour cells, telomere length (TL) is maintained by reactivation of telomerase, while a small part acquires immortality through the telomerase-independent alternative lengthening of telomeres (ALT) mechanism. In the last years, a great amount of data was gen...
TERT, BRAF and NRAS in primary thyroid cancer and metastatic disease
Melo, M; Gaspar da Rocha, A; Batista, R; Vinagre, J; Martins, MJ; Costa, G; Ribeiro, C; Carilho, F; Leite, V; Lobo, C; Cameselle-Teijeiro, JMContext: Little is known about the frequency of key mutations in thyroid cancer metastases and its relationship with the primary tumor genotype. Objectives: To evaluate the frequency of TERT promoter (TERTp), BRAF, and NRAS mutations in metastatic thyroid carcinomas, analyzing primary thyroid tumors, lymph node metastases (LNMs), and distant metastases. Design and Patients: Mutation analysis was performed in 43...